STOCK TITAN

Icon Plc - ICLR STOCK NEWS

Welcome to our dedicated page for Icon Plc news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on Icon Plc stock.

ICON plc (ICLR) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Ireland, ICON specializes in the strategic development, management, and analysis of clinical programs that support clinical development from compound selection to phase I-IV clinical studies.

Operating in a highly fragmented industry, ICON is among a select group of organizations with the capability and expertise to conduct clinical trials and development projects on both a local and global scale. The company's core services are versatile, offering both standalone and integrated full-service solutions to meet diverse client needs. This operational flexibility ensures that ICON can tailor its services to individual project requirements.

ICON's array of services includes end-to-end pharmacovigilance, which covers post-marketing surveillance activities. The company also provides ancillary services, such as laboratory and imaging capabilities, enhancing its comprehensive approach to drug development and clinical research.

This robust service offering positions ICON as a pivotal partner for firms aiming to bring their medical innovations to market. Recent achievements and ongoing projects underscore ICON's commitment to excellence and innovation in clinical research. The company's financial health remains strong, supported by strategic partnerships and a global client base.

Stay updated on ICON plc's latest developments, performance updates, and industry news to understand the significant role this organization plays in advancing healthcare solutions worldwide.

News
Rhea-AI Summary
ICON plc reports Q3 2023 financial results with net business wins of $2.6 billion and revenue growth of 5.8% YoY. Adjusted EBITDA and adjusted earnings per share increased by 13.9% and 10% respectively. The company reaffirms its full-year 2023 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.78%
Tags
-
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) upgraded to investment grade credit rating of BBB- by S&P Global Ratings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
none
-
Rhea-AI Summary
ICON plc to release Q3 2023 financial results on October 25, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
Rhea-AI Summary
ICON plc announces release of next generation Clinical Trial Tokenisation solution
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
-
Rhea-AI Summary
ICON plc partners with BARDA to conduct clinical trial for next generation COVID-19 vaccine candidates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
partnership clinical trial covid-19
-
Rhea-AI Summary
ICON plc CEO to present at Baird Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
conferences
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) Announces Successful Passing of All Resolutions at the Annual General Meeting, Including Re-election of Board Members and Authorization for Share Allotment and Market Purchases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
-
News
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) reported net business wins of $2,419 million in Q2 2023, with a closing backlog of $21.7 billion. Quarter two revenue increased by 4.4%, and adjusted EBITDA rose by 16.9%. The company updated its full-year 2023 financial guidance, expecting revenue in the range of $8,070 - $8,210 million, representing a year-over-year increase of 4.3 to 6.1%, and adjusted earnings per share in the range of $12.63 - $12.91, reflecting a year-over-year increase of 7.5 to 9.9%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
-
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) received multiple awards in 2023, including the 2023 CRO Leadership Awards for Capabilities, Compatibility, Expertise, Quality, and Reliability. They were also recognized as a top employer and received the 2023 Global Impact Award for their role in the search for COVID-19 vaccines and treatments. CEO Steve Cutler emphasized the importance of driving positive outcomes and value for customers and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags

FAQ

What is the current stock price of Icon Plc (ICLR)?

The current stock price of Icon Plc (ICLR) is $207.51 as of December 20, 2024.

What is the market cap of Icon Plc (ICLR)?

The market cap of Icon Plc (ICLR) is approximately 16.9B.

What services does ICON plc provide?

ICON plc provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries, including clinical trial management, laboratory, and imaging capabilities.

Where is ICON plc headquartered?

ICON plc is headquartered in Ireland.

What is ICON's role in pharmaceutical development?

ICON specializes in the strategic development, management, and analysis of clinical programs, supporting clinical development from compound selection to phase I-IV clinical studies.

Does ICON offer standalone and integrated services?

Yes, ICON provides both standalone and integrated full-service solutions to meet diverse client needs.

What is pharmacovigilance, and does ICON provide it?

Pharmacovigilance involves monitoring the effects of drugs after they have been licensed for use to ensure they are safe. ICON offers end-to-end pharmacovigilance services, including post-marketing surveillance.

What industries does ICON serve?

ICON serves the pharmaceutical, biotechnology, and medical device industries.

What makes ICON a leader in its industry?

ICON's capability to conduct clinical trials globally, strong financial health, strategic partnerships, and comprehensive service offerings make it a leader in the industry.

How can I stay updated on ICON's latest news and developments?

You can stay updated on ICON's latest news and developments by visiting reputable stock market websites or ICON's official website.

What are some of ICON's ancillary services?

ICON offers ancillary services, including laboratory and imaging capabilities, to support drug development and clinical research.

What type of clients does ICON work with?

ICON works with clients in the pharmaceutical, biotechnology, and medical device industries, providing them with comprehensive development and clinical trial services.

Icon Plc

Nasdaq:ICLR

ICLR Rankings

ICLR Stock Data

16.93B
81.85M
0.66%
101.13%
1.55%
Diagnostics & Research
Healthcare
Link
United States of America
Dublin